Semapimod sensitizes glioblastoma tumors to ionizing radiation by targeting microglia

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Miller, Ian S ^a,b   Didier, Sebastien ^a   Murray, David W ^a,b   Turner, Tia H ^a   Issaivanan, Magimairajan ^a,c   Ruggieri, Rosamaria ^a   Al Abed, Yousef ^a   Symons, Marc ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c Pediatric Neuro Oncology Cancer Care Manitoba   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

SEMAPIMOD; HYDRAZONE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; RADIOSENSITIZING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL INVASION; CELL PROLIFERATION; CELL STIMULATION; CELL STRAIN; CELL STRAIN GL261; CELL SURVIVAL; CONTROLLED STUDY; DRUG TARGETING; GLIOBLASTOMA; GLIOMA CELL; IN VITRO STUDY; IONIZING RADIATION; MACROPHAGE FUNCTION; MALE; MICROGLIA; MOUSE; NONHUMAN; RADIOSENSITIVITY; RADIOSENSITIZATION; SERUM; TARGET CELL; ANIMAL; APOPTOSIS; BRAIN NEOPLASMS; C57BL MOUSE; CELL CULTURE; CELL MOTION; CHEMORADIOTHERAPY; DRUG EFFECTS; MACROPHAGE; PATHOLOGY; RADIATION RESPONSE; SURVIVAL; TUMOR CELL LINE; TUMOR INVASION; TUMOR VOLUME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CHEMORADIOTHERAPY; GLIOBLASTOMA; HYDRAZONES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; NEOPLASM INVASIVENESS; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; SURVIVAL ANALYSIS; TUMOR BURDEN;

EID: 84901288344     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095885     Document Type: Article

References (37)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10: 459-66.
2. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, et al. (2010) Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J. Clin. 60: 166-93.
3. Hanisch UK, Kettenmann H (2007) Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 10: 1387-94.
4. Ransohoff RM, Cardona AE (2010) The myeloid cells of the central nervous system parenchyma. Nature 468: 253-62.
5. Li W, Graeber MB (2012) The molecular profile of microglia under the influence of glioma. Neuro. Oncol. 14: 958-78.
6. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H (2012) The brain tumor microenvironment. Glia 60: 502-14.
7. da Fonseca AC, Badie B (2013) Microglia and macrophages in malignant gliomas: recent discoveries and implications for promising therapies. Clin. Dev. Immunol, doi: 10.1155/2013/264124.
8. Roggendorf W, Strupp S, Paulus W (1996) Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol. 92: 288-93. (Pubitemid 26278960)
9. Komohara Y, Ohnishi K, Kuratsu J, Takeya M (2008) Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 216: 15-24.
10. Kostianovsky AM, Maier LM, Anderson RC, Bruce JN, Anderson DE (2008) Astrocytic regulation of human monocytic/microglial activation. J. Immunol. 181: 5425-32.
11. Markovic DS, Vinnakota K, Chirasani S, Synowitz M, Raguet H, et al. (2009) Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc. Natl. Acad. Sci. U. S. A. 106: 12530-5.
12. Zhai H, Heppner FL, Tsirka SE (2011) Microglia/macrophages promote glioma progression. Glia 59: 472-85.
13. Bianchi M, Ulrich P, Bloom O, Meistrell M, III, Zimmerman GA (1995) An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality. Mol. Med. 1: 254-66.
14. Bianchi M, Bloom O, Raabe T, Cohen PS, Chesney J (1996) Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J. Exp. Med. 183: 927-36. (Pubitemid 26114796)
15. Bjork L, Tracey KJ, Ulrich P, Bianchi M, Cohen PS (1997) Targeted suppression of cytokine production in monocytes but not in T lymphocytes by a tetravalent guanylhydrazone (CNI-1493). J. Infect. Dis. 176: 1303-12. (Pubitemid 27460997)
16. Lowenberg M (2007) Proximal signaling molecules as potential targets for anti-inflammatory therapy. Curr. Opin. Drug Discov. Devel. 10: 560-4.
17. Dotan I, Rachmilewitz D, Schreiber S, Eliakim R, van der Woude CJ, et al. (2010) A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. Gut. 59: 760-6.
18. Dobrenis K (1998) Microglia in cell culture and in transplantation therapy for central nervous system disease. Methods 16: 320-44.
19. Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, et al. (2012) Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling. Mol. Med. 18: 519-27.
20. Bettinger I, Thanos S, Paulus W (2002) Microglia promote glioma migration. Acta Neuropathol. (Berl) 103: 351-5. (Pubitemid 36097029)
21. Wesolowska A, Kwiatkowska A, Slomnicki L, Dembinski M, Master A, et al. (2008) Microglia-derived TGF-beta as an important regulator of glioblastoma invasion-an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor. Oncogene 27: 918-30. (Pubitemid 351225378)
22. Jacobs VL, Landry RP, Liu Y, Romero-Sandoval EA, De Leo JA (2012) Propentofylline decreases tumor growth in a rodent model of glioblastoma multiforme by a direct mechanism on microglia. Neuro. Oncol. 14: 119-31.
23. Squatrito M, Holland EC (2011) DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. Cancer Res. 71: 5945-9.
24. Maes W, Van Gool SW (2011) Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunol. Immunother. 60: 153-60.
25. Gabrusiewicz K, Ellert-Miklaszewska A, Lipko M, Sielska M, Frankowska M, et al. (2011) Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS. One. 6:e23902.
26. Zinser E, Turza N, Steinkasserer A (2004) CNI-1493 mediated suppression of dendritic cell activation in vitro and in vivo. Immunobiology 209: 89-97. (Pubitemid 39255695)
27. Lowenberg M, Verhaar A, van den BB, ten Kate F, van Deventer S, et al. (2005) Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease. J. Immunol. 175: 2293-300. (Pubitemid 41113837)
28. Cohen PS, Nakshatri H, Dennis J, Caragine T, Bianchi M (1996) CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. Proc. Natl. Acad. Sci. U. S. A. 93: 3967-71. (Pubitemid 26146719)
29. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, et al. (2013) CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. doi.: 10. 1038./nm. 3337.10.
30. Ruffell B, Affara NI, Coussens LM (2012) Differential macrophage programming in the tumor microenvironment. Trends Immunol. 33: 119-26.
31. Meng Y, Beckett MA, Liang H, Mauceri HJ, van Rooijen N (2010) Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res. 70: 1534-43.
32. Denardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, et al. (2011) Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discov. 1: 54-67.
33. Gursel DB, Berry N, Boockvar JA (2012) Therapeutic stem cells encapsulated in a synthetic extracellular matrix selectively kill tumor cells, delay tumor growth, and increase survival in a mouse resection model of malignant glioma. Neurosurgery 70: N17-N19.
34. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, et al. (2011) Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl. Acad. Sci. U. S. A. 108: 3749-54.
35. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, et al. (2012) VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell. 22: 21-35.
36. Atkins MB, Redman B, Mier J, Gollob J, Weber J, et al. (2001) A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma. Clin. Cancer Res. 7: 486-92. (Pubitemid 32707969)
37. Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, et al. (2002) Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology. 122: 7-14. (Pubitemid 34049188)